SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Bliss GVS Pharma Ltd

BSE: 506197 NSE: BLISSGVS ISIN: INE416D01022
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Bliss GVS Pharma Ltd belong to?
Bliss GVS Pharma Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Bliss GVS Pharma Ltd a good quality company?
Bliss GVS Pharma Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Bliss GVS Pharma Ltd undervalued or overvalued?
Bliss GVS Pharma Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Bliss GVS Pharma Ltd a good buy now?
Bliss GVS Pharma Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd revenue growth is 10.2% for FY-2025 , which is above its 5 year CAGR of 8.6% , indicating faster growth.
Q.2 Gross Profit margin of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Gross profit margin which is the profit after deduction of direct costs, is 18.2% for FY-2025 , which is below its 5 year median of 21.9% , indicating decreasing margins.
Q.3 Operating Profit Margin of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 13.77% for FY-2025 , which is below its 5 year median of 17.16% indicating decreasing margins.
Q.4 Net Profit Margin of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Net Profit Margin is 10.34% for FY-2025 , is below with its 5 year median of 14.29%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 18.2 21.9
Operating Profit Margin 13.77 17.16
Net Profit Margin 10.34 14.29
Q.5 Return on Asset of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Return on Asset is 5.85%, which is below its 5 year historical median of 7.5%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Return on equity is 6.78% for FY-2025 , which is below its historical median of 9.45%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Return on capital employed is 9.31% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Cash conversion cycle is 236 days, above its historical median of 236 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.57 0.54
ROE 6.78 9.45
ROCE 9.31 12.02
Cash Conversion Cycle 236 days 236 days
Q.9 Debt to Equity ratio of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Debt-to-Equity ratio is 0.05 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd Debt to cash flow from operations is 0.52 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Bliss GVS Pharma Ltd?
Promoters hold 35.36% of the Bliss GVS Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Bliss GVS Pharma Ltd vs industry peers?
Bliss GVS Pharma Ltd revenue CAGR is 8.59% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 667.2 137.1
Gross Profit 121.4 15.1
Operating Profit 92 16
Net Profit 69 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.57 0.8
ROE 6.78 8.91
ROCE 9.31 11.59
Cash Conversion Cycle (days) 235.62 76

Valuation & price assessment

Q.1 Stock return of Bliss GVS Pharma Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 6.6% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 6.6% 22% 52.1% 107.9%
Q.3 Valuation ratios of Bliss GVS Pharma Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 36.14 18.89 40.28
Price to Book 2.44 2.31 2.77
Price to Sales 4.07 3.67 2.65
EV to EBITDA 17.88 13.05 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×